Quantitative Total Extensible Imaging (QTxI)

by AIQ Solutions  · Based in United States → — Optimizing late-stage cancer care through quantitative and spatial analysis of treatment response heterogeneity.
Nuclear Medicine Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

Quantitative Total Extensible Imaging (QTxI) is a software tool developed by AIQ Solutions to aid trained medical professionals in the evaluation and information management of digital medical images. Cleared by the FDA, QTxI is designed for use by radiologists, oncologists, nuclear medicine physicians, medical imaging technologists, dosimetrists, and physicists. The software operates on DICOM CT and PET modalities, supporting ACR/NEMA DICOM 3.0 standards. Its core functionalities include receiving, storing, retrieving, displaying, and processing digital medical images. QTxI enables the identification and contouring of Regions of Interest (ROIs), facilitating quantitative and statistical analysis of full or partial-body scans through registration to template space. The tool provides 3D interactive rendering of images with highlighted ROIs and, at the time of its FDA clearance, included the Quantitative Total Bone Imaging (QTBI) module for identifying and measuring hot-spots on PET scans. AIQ Solutions has since evolved its technology, with TRAQinform IQ being a modification of QTxI, also FDA-cleared, focusing on quantifying changes in regions of interest over time to optimize late-stage cancer care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Evaluation and information management of digital medical images (DICOM CT and PET)
  • Display, registration, and fusion of medical images from multiple modalities
  • Identification and contouring of Regions of Interest (ROIs)
  • Quantitative and statistical analysis of full or partial-body scans
  • 3D interactive rendering of images with highlighted ROIs
  • Automated quantification of ROIs and changes in ROIs (via QTBI module)
  • Cloud-based HIPAA-compliant data pipelines
  • Automated report generation
  • Lesion-level longitudinal quantitative imaging
  • Radiomics and lesion heterogeneity metrics
  • Integration into existing clinical workflows

Use Cases

  • Optimizing late-stage cancer care
  • Monitoring treatment response in metastatic cancer (e.g., lung, lymphoma, prostate, bladder, head and neck, neuroendocrine system, melanoma)
  • Aiding oncologists/clinicians in adjusting therapies and optimizing clinical outcomes
  • Personalized medicine through analysis of individual patient treatment response
  • Quantitative assessment of early treatment response
  • Evaluating lesion response heterogeneity for prognostication

What Physicians Need to Know

Key Capabilities
QTxI (TRAQinform IQ) is a software medical device that analyzes serial radiographic images (PET, CT) to quantify changes in regions of interest over time. It provides novel information about the quantification of change in regions of interest over time, focusing on treatment response heterogeneity and personalized medicine. The technology automatically detects and quantifies lesions using diagnostic CT images and measures lesion-wise response over multiple scans. It can detect lesions in various organs, including bone, lymph node, liver, breast, lung, pancreas, bowel, and kidney. The software generates comprehensive reports to support oncologist decision-making, enabling more precise therapy adjustments and optimized clinical outcomes. QTxI also leverages AI/machine learning for predictive modeling and offers cloud-based HIPAA-compliant data pipelines and automated report generation.
Clinical Utility
QTxI assists oncologists, radiation oncologists, and nuclear medicine physicians in understanding how individual lesions respond to cancer treatment, especially in late-stage cancer care. It helps in identifying intra-patient heterogeneity of treatment response, where different lesions within the same patient may respond differently to therapy. This information can be used to tailor treatment regimens, optimize outcomes, and make more informed decisions about continuing, adding, or switching treatments. Studies have shown that QTxI's analysis of lesion changes is more prognostic of overall survival than standard-of-care methods like RECIST and PERCIST in metastatic lung cancer and lymphoma.
Integration Options
QTxI is designed for easy integration into existing clinical workflows. Images can be electronically sent from hospitals or imaging centers to AIQ Solutions via a HIPAA-compliant cloud. AIQ Solutions has partnered with Blackford Analysis to integrate its technology with Blackford's enterprise AI platform, aiming to expand reach to more clinicians. AIQ also offers platform integration with research data management systems.
Compliance Status
TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444. AIQ Solutions ensures comprehensive data protection, traceability, and auditability, adhering to rigorous industry standards, including HIPAA. The American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT) code for AIQ's TRAQinform IQ technology, specifically for determining heterogeneity of change across all lesions for advanced metastatic cancer.
Pricing Model
While specific pricing for QTxI is not publicly disclosed, AI imaging tools in general are priced in various ways, including per-study subscription, annual site license, per-user license, or a bundled fee. The average price for imaging & diagnostics AI is typically $5-15 per study, with a range of $3-$25 per study. Enterprise pricing can range from $3-$10 per study with volume tiers. Factors affecting pricing include the volume of studies, modalities covered, number of AI models deployed, and PACS integration requirements.
User Experience
The software is designed to provide clear, comprehensive reports detailing how each area in a patient's body is changing during treatment. This information is intended to empower oncologists and clinicians to make confident decisions.
Support Quality
AIQ Solutions emphasizes a commitment to quality and excellence, working collaboratively to deliver successful products that impact patients and clinicians. They offer research collaborations and clinical validation support.
Implementation Complexity
QTxI is designed for easy integration into existing workflows, with images sent electronically via a HIPAA-compliant cloud. AIQ Solutions also offers integration and deployment services to connect imaging analysis pipelines with cloud-scale research data management and collaboration platforms.
Evidence Base
AIQ Solutions has a strong evidence base, with numerous publications, clinical research, and poster presentations supporting its technology platform. Retrospective studies have shown QTxI to be more prognostic of overall survival than standard-of-care methods in certain metastatic cancers. The technology has demonstrated its ability to detect and segment lesions and quantify lesion-wise change over time on diagnostic CT images. Research collaborations and clinical validation support are ongoing, including studies on immunotherapy response prediction and theranostics.
Physician Tip

When using QTxI, focus on the detailed, lesion-level quantitative data provided to identify treatment response heterogeneity, which can be crucial for optimizing therapy in late-stage cancer patients. The software's ability to analyze all lesions, rather than a limited subset, offers a more comprehensive understanding of disease progression. Integrate this information with your clinical judgment and other patient data to make personalized treatment adjustments. Remember that while the AMA has approved a Category III CPT code for this technology, these codes are primarily for tracking and may not be eligible for direct reimbursement, so consider the financial implications for your practice.

QTxI is designed for straightforward integration into existing clinical workflows, primarily through cloud-based image submission. Its partnership with Blackford's enterprise AI platform suggests broader compatibility with hospital imaging ecosystems. For research purposes, it can integrate with research data management systems. Ensure your institution's IT infrastructure supports secure, HIPAA-compliant cloud data transfer for optimal utilization.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

What the Web Says

Quantitative Total Extensible Imaging (QTxI) by AIQ Solutions is a software tool designed to aid medical professionals in the evaluation and information management of digital medical images, specifically DICOM CT and PET studies. It assists with tasks such as registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative imaging biomarkers. QTxI is FDA-cleared and is intended for use by trained medical professionals including radiologists, oncologists, nuclear medicine physicians, medical imaging technologists, dosimetrists, and physicists.

Overall: Positive

Strengths

  • Aids in evaluation and information management of digital medical images.
  • Supports DICOM CT and PET studies.
  • Assists with registration, fusion, and region-of-interest contouring.
  • Enables quantitative analysis and evaluation of quantitative imaging biomarkers.
  • FDA-cleared.
  • Used by a range of medical professionals including radiologists, oncologists, and nuclear medicine physicians.

Limitations

No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.

Based on reviews from: indeed.com, physicianaitools.com, parikhradiology.com, gencat.cat, nih.gov, innolitics.com

Last updated: 2026-10-28

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Quantitative Total Extensible Imaging (QTxI)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

fda.gov
AIQ GLOBAL, INC. SUBSTANTIALLY EQUIVALENT47, 1. AIQ SOLUTIONS, INC. SUBSTANTIALLY EQUIVALENT48, 1. 1. K173444 Quantitative Total Extensible Imaging (QTxI)49.
This FDA document indicates that AIQ Solutions, Inc.'s Quantitative Total Extensible Imaging (QTxI) has received a substantial equivalence determination.
2026-10
physicianaitools.com
Quantitative Total Extensible Imaging (QTxI)
QTxI, offered by AIQ Solutions, provides a comprehensive suite of tools for evaluating and managing digital medical images, including display, registration, fusion of images from multiple modalities, and identification and contouring of Regions of Interest (ROIs). It is an FDA-cleared, cloud-based AI tool for quantitative analysis of PET/CT scans in oncology, emphasizing multi-modality image fusion and 3D rendering capabilities.
unknown
gencat.cat
AIQ Solutions. Quantitative Total Extensible Imaging (QTxI) is a software tool used to aid in evaluation and information management of digital medical images by trained medical professionals including, but not limited to, radiologists, oncologists, nuclear medicine physicians, medical imaging technologists, dosimetrists and physicists.
Quantitative Total Extensible Imaging (QTxI) by AIQ Solutions is a software tool designed for medical professionals to evaluate and manage digital medical images, supporting DICOM CT and PET modalities for tasks like image display, registration, fusion, and quantitative analysis of Regions of Interest (ROIs).
2021-04
physicianaitools.com
Quantitative Total Extensible Imaging (QTxI) is ... Videos. News, demos, and interviews about AIQ Solutions. ... AIQ Global. AIQ Solutions Announces a New ...
Quantitative Total Extensible Imaging (QTxI) is an FDA-cleared software tool from AIQ Solutions for medical professionals to evaluate and manage digital medical images.
unknown
orthogonal.io
SaMD Cleared by the FDA: The Ultimate Running List.
AIQ Solutions, Inc.'s Quantitative Total Extensible Imaging (QTxI) was cleared by the FDA on July 23, 2018, for use in radiology.
2024-10
nih.gov
Quantitative Total Extensible Imaging (QTxi), AIQ Solutions, Inc. Create ROI contours for quantitative/statistical analysis and dosimetry, K173444, 2018.
Quantitative Total Extensible Imaging (QTxI) by AIQ Solutions, Inc. received FDA clearance (K173444) in 2018 for creating ROI contours for quantitative/statistical analysis and dosimetry.
2018
fda.gov
510(k) Premarket Notification.
AIQ Solutions, Inc. received 510(k) premarket notification for Quantitative Total Extensible Imaging (QTxI) on July 23, 2018.
2018-07
warrick.net
Quantitative Total Extensible Imaging (QTxI) · AIQ Solutions, Inc. K233998 · 12/18/2023 · TRAQinform IQ · AIQ Global, Inc. Search | Companies | Product Codes
AIQ Solutions, Inc. received FDA clearance (K233998) for Quantitative Total Extensible Imaging (QTxI) on December 18, 2023.
2023-12

Videos

Product demos, reviews, and walkthroughs for Quantitative Total Extensible Imaging (QTxI).

View all on YouTube

Frequently Asked Questions

AIQ Solutions' QTxI technology, specifically TRAQinform IQ, is a software medical device that analyzes serial radiographic images, such as PET/CT and diagnostic CT scans, to quantify changes in regions of interest over time. This provides novel, quantitative, and spatial information about each lesion, assisting oncologists in adjusting therapies and optimizing clinical outcomes, particularly in late-stage cancer care.
AIQ Solutions' QTxI software, TRAQinform IQ, is cleared by the FDA for clinical use to assist with quantitative oncology imaging analysis and treatment response assessment. This indicates it meets regulatory standards for medical devices. The system also uses secure cloud workflows for image analysis and reporting, which is important for HIPAA compliance.
Traditional methods like RECIST guidelines have been used for evaluating treatment response in oncology, but they have limitations, such as inconsistency in target lesion identification and limited evaluation of only a few lesions. Other quantitative imaging analysis tools and platforms exist, with some focusing on specific imaging modalities or research applications, such as those supported by the National Cancer Institute's Quantitative Imaging Network (QIN).
While specific pricing for AIQ Solutions' QTxI is not publicly available, the broader AI in oncology market is experiencing significant growth, projected to reach $11.52 billion by 2030. Some quantitative imaging services are offered for a nominal fee, including 2D tumor metrics, 3D volumetrics, and advanced image analysis. However, the cost of implementing AI technologies in clinical settings can be a significant barrier, especially for smaller institutions.
While QTxI offers advanced quantitative analysis, general limitations of AI in oncology include concerns about data quality, potential biases in algorithms, and the need for robust validation in real-world settings. Clinician mistrust due to a lack of understanding of AI mechanisms and potential over-reliance on technology are also considerations. Additionally, the technology relies on the availability of serial radiographic images.
AIQ Solutions' TRAQinform IQ technology has shown to be more prognostic of overall survival than standard-of-care methods, including RECIST, PERCIST, global SUVpeak, and global volume, in retrospective studies of patients with metastatic lung cancer and lymphoma. RECIST guidelines often focus on a limited number of target lesions, which can miss intra-patient heterogeneity of treatment response. QTxI aims to overcome this by automatically detecting and quantifying all lesions and measuring lesion-wise response over multiple scans.

Compare Quantitative Total Extensible Imaging (QTxI)

VS
Quantitative Total Extensible Imaging (QTxI) vs Viz CTP
Clinical Decision Support & Reference Adjacent · 65/100
Tool A is designed for quantitative analysis and monitoring of medical images, primarily for oncology treatment assessment, focusing on detailed ROI evaluation. Tool B specializes in AI-powered disease…
VS
Quantitative Total Extensible Imaging (QTxI) vs ContaCT
Clinical Decision Support & Reference Adjacent · 60/100
Tool A (QTxI) specializes in quantitative analysis of medical images for detailed treatment monitoring, particularly in oncology, focusing on ROI quantification and change detection. Tool B (ContaCT) is…
VS
Quantitative Total Extensible Imaging (QTxI) vs Viz SDH
Clinical Decision Support & Reference Adjacent · 65/100
Tool A (QTxI) is a comprehensive platform for quantitative analysis and management of digital medical images, primarily focused on oncology treatment monitoring. In contrast, Tool B (Viz SDH)…
VS
Quantitative Total Extensible Imaging (QTxI) vs Viz Subdural+
Clinical Decision Support & Reference Adjacent · 65/100
QTxI offers a broad platform for quantitative analysis of CT and PET images, primarily aiding in general treatment monitoring and oncology. Viz Subdural+, conversely, is a highly specialized…

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-10-14 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.